

REMARKS


Claims 1-22, 32-89, and 91-94 have been cancelled, and claim 90 has been amended, solely in order to pursue one of the disclosed embodiments. Cancellation of the remaining claims is not to be construed as an acquiescence of any kind and such claims will be pursued in a later filed continuation or continuation-in-part application.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "**Version With Markings to Show Changes Made.**"

Respectfully submitted,

Emad S. Alnemri

Seed Intellectual Property Law Group PLLC



Karl R. Hermanns
Registration No. 33,507

WTC:jto

Enclosure:
Postcard

701 Fifth Avenue, Suite 6300
Seattle, Washington 98104-7092
Phone: (206) 622-4900
Fax: (206) 682-6031

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Claims:

Claims 1-22, 32-89, and 91-94 have been canceled.

Claim 90 has been amended as follows:

90. (Amended) A composition comprising a peptide selected from the group consisting of claims 23 – 31 ~~and 35~~ – 39, and a physiologically acceptable carrier.

D:\NrPortbl\iManage\JOHNO\282714_1.DOC